Age-related macular degeneration (AMD) affects millions of Americans, particularly those over 65, making it the leading cause of vision loss in this age group. While many patients are familiar with treatments for wet AMD, the large population of patients with dry AMD have historically had fewer options – until now.
Mann Eye Institute is proud to offer cutting-edge treatment using the Valeda Light Delivery System by LumiThera, an FDA-authorized therapy that harnesses the power of light to address dry AMD.
What Is the Valeda Light Delivery System?
Using targeted light therapy, the Valeda Light Delivery System helps rejuvenate cells in the retina. The system delivers precise doses of yellow, red, and near-infrared light to affected eye tissue, which may help prevent further vision loss and improve sight. Mann Eye Institute has added this innovative, non-invasive treatment to their range of eye care services for patients.
Who Can Benefit from Valeda Treatment?
Valeda treatment is for people with dry age-related macular degeneration (dry AMD) who:
- Can see moderately well with corrected vision (roughly able to read the bigger letters on an eye chart)
- Have small to medium-sized yellow deposits (called drusen) under their retina
- Have some damage to the retina, but not in the center of their vision
- Don’t have abnormal blood vessel growth or central vision damage
Studies show that people who receive Valeda treatment typically can read about one extra line on an eye chart compared to untreated patients after about two years of therapy.
The Treatment Experience
During a Valeda treatment session at Mann Eye Institute, patients sit comfortably while the system delivers therapeutic light to the retina. The procedure is non-invasive, painless, and typically completed in minutes. Our ophthalmologists develop personalized treatment plans based on each patient’s specific condition and needs.
Important Safety Considerations
While Valeda therapy is safe for most patients, certain individuals should not undergo this treatment, including those with:
- Known sensitivity to yellow light, red light, or near-infrared radiation
- History of light-activated central nervous system conditions (such as epilepsy or migraines)
- Recent use of photosensitizing medications or agents (within 30 days)
Our team at Mann Eye Institute conducts thorough evaluations before recommending Valeda treatment to ensure it’s appropriate for each patient’s unique situation.
The Future of Dry AMD Management
What makes the Valeda system particularly promising is its ability to address a condition that has historically had limited treatment options. Mann Eye Institute remains at the forefront of adopting innovative technologies that provide hope and practical solutions for patients facing challenging retinal conditions like dry AMD.
For patients experiencing vision changes or those diagnosed with dry AMD, we encourage scheduling a consultation with our retina specialists to learn if Valeda light therapy might be beneficial. Early intervention with appropriate treatments offers the best opportunity to preserve vision and maintain quality of life.